Insulin Degludec

Insulin Degludec is a long-acting, basal insulin analogue used to help maintain blood glucose control in people with diabetes mellitus. It is a modified form of human insulin designed to form multi-hexamers after subcutaneous injection, creating a depot from which insulin is released gradually into the bloodstream. This slow, sustained absorption provides a prolonged glucose-lowering effect lasting beyond 24 hours in many patients and helps control glucose between meals and overnight. Like natural insulin, insulin degludec binds to insulin receptors, promotes glucose uptake by muscle and fat cells, and reduces glucose production by the liver. It is administered by subcutaneous injection, generally once daily, using an authorised insulin pen or other approved presentation. In type 1 diabetes, it must be combined with mealtime insulin; in type 2 diabetes, it may be used alone or alongside other glucose-lowering medicines, depending on the treatment plan. Its long duration can provide flexibility in daily injection timing within the limits specified by the product information, but doses must still be taken consistently and adjusted carefully. Hypoglycaemia is the main safety concern, so patients require appropriate glucose monitoring, education on low blood glucose, and regular clinical review.

Insulin degludec was developed as an ultra-long-acting basal insulin analogue to provide prolonged and relatively stable insulin exposure after subcutaneous injection. Its molecular modifications allow it to form multi-hexamers in subcutaneous tissue, from which insulin monomers are released gradually. The European Medicines Agency evaluated the medicine through clinical studies in adults and children with diabetes, including the BEGIN clinical trial programme, which compared insulin degludec with other basal insulin treatments. The European Commission granted marketing authorisation for Tresiba on 21 January 2013 following a positive scientific assessment by the EMA. Regulatory approvals and approved age groups vary by country and product presentation. Clinical studies assessed long-term blood glucose control, HbA1c outcomes, and hypoglycaemia, including nocturnal episodes. Current local prescribing information should be consulted for the approved indications, available strengths, administration instructions, and safety requirements.

Insulin Degludec is used to improve blood glucose control in people with type 1 or type 2 diabetes mellitus, subject to the approved age groups and indications in the relevant country. In type 1 diabetes, it is used as basal insulin alongside rapid-acting or short-acting mealtime insulin. In type 2 diabetes, it may be prescribed alone or in combination with other glucose-lowering medicines, including oral medicines, GLP-1 receptor agonists, or mealtime insulin when clinically appropriate. Its prolonged action helps manage blood glucose between meals and overnight, while other components of a treatment regimen may be needed to control glucose rises after eating. The choice of insulin and combination therapy depends on glucose measurements, previous treatment, hypoglycaemia risk, kidney and liver function, lifestyle, and individual treatment goals.

Insulin Degludec is administered by subcutaneous injection, usually once daily, into the abdomen, thigh, or upper arm, with injection sites rotated to reduce changes in the fatty tissue under the skin. The dose is individualised according to diabetes type, previous insulin treatment, blood glucose results, meals, activity, and other medicines. Adults with type 2 diabetes starting basal insulin may commonly begin with 10 units once daily, while people with type 1 diabetes generally require an individualised basal dose as part of a regimen that includes mealtime insulin. Patients switching from another insulin require clinician-directed dose selection and closer glucose monitoring. The product information permits some flexibility in injection timing for adults, but doses should remain separated according to the prescribed minimum interval and the applicable label. Insulin Degludec must not be administered intravenously or used in an insulin pump unless specifically authorised for that presentation. Blood glucose should be monitored regularly, and dose adjustments should be made under professional guidance. Treatment is generally continued long term when required to manage diabetes.

The most important common side effect of Insulin Degludec is hypoglycaemia, or low blood glucose, which may cause sweating, trembling, hunger, dizziness, headache, palpitations, or difficulty concentrating. Other possible effects include injection-site redness, swelling, itching, or discomfort, weight gain, and changes in the fatty tissue under the skin if injections are repeatedly given in the same area. Peripheral oedema, or swelling of the limbs, may occur in some patients. Side effects vary according to dose, meal intake, physical activity, other medicines, and individual response. Patients should learn to recognise and manage low blood glucose, follow their prescribed injection schedule, and seek advice if episodes recur or injection-site changes develop. Persistent glucose fluctuations or unexpected weight changes should be discussed with the treating healthcare professional.

Severe hypoglycaemia can cause seizures, loss of consciousness, or death and requires urgent treatment. Serious allergic reactions are uncommon but may involve widespread rash, swelling of the face or throat, or difficulty breathing. Insulin can lower blood potassium, potentially causing dangerous heart rhythm disturbances in susceptible patients. Fluid retention and worsening heart failure may occur when insulin is combined with certain medicines, including thiazolidinediones. Changes in insulin dose, meal patterns, physical activity, illness, or other medicines can significantly alter blood glucose and increase the risk of hypoglycaemia or hyperglycaemia. Insulin Degludec must not be used during an episode of hypoglycaemia or in patients with a serious allergy to its ingredients. It should not be stopped without medical advice, particularly in type 1 diabetes, because inadequate insulin can lead to diabetic ketoacidosis. Any interruption, dose change, or switch to another insulin should be planned and monitored by a healthcare professional.

Patients with kidney or liver impairment may need closer monitoring because insulin requirements can change. Additional care is appropriate for older adults, people with reduced awareness of hypoglycaemia, patients with irregular food intake, and those who have recently changed their activity level or insulin regimen. Pregnancy and breastfeeding require individualised treatment planning and regular clinical review. Other glucose-lowering medicines, some antidepressants, salicylates, and certain blood pressure medicines may increase the glucose-lowering effect of insulin. Corticosteroids, some diuretics, thyroid hormones, sympathomimetic medicines, and some antipsychotics may increase blood glucose or change insulin requirements. Beta-blockers can mask some warning signs of hypoglycaemia, and alcohol may increase the risk of low blood glucose. Injection sites should be rotated, and patients should not share insulin pens or needles. Insulin Degludec should be stored and handled according to the specific product instructions, protected from excessive heat and light, and never frozen.

Before initiating treatment, assess the patient's diabetes history, current medicines, previous insulin exposure, glucose records, hypoglycaemia risk, kidney and liver function, and ability to use the injection device correctly. Explain the difference between basal insulin and mealtime insulin, especially for patients with type 1 diabetes, who require appropriate mealtime insulin alongside Insulin Degludec. Confirm the prescribed concentration and device to reduce medication errors, as different strengths may be available. Teach correct injection technique, site rotation, dose recording, storage, and safe sharps disposal. Patients should receive clear guidance on recognising and managing hypoglycaemia, checking glucose during illness, and obtaining urgent help when necessary. Review glucose readings after treatment initiation, dose changes, or switches from another insulin, and reassess the regimen when diet, activity, kidney function, or concomitant medicines change. Reinforce that the medicine should not be discontinued without a clinician-directed alternative and that treatment decisions should be based on glucose results and individual clinical needs.